Sally Pipes
@sallypipes
President, CEO, Thomas W. Smith Fellow in Health Care Policy @PacificResearch. Author: The World's Medicine Chest
3.9K Following 8.6K Followers
Two-thirds of Americans support Medicare for All, according to a new KFF poll. But mention the possibility of longer waits for medical care, and support plummets to just 24%.
Who would be enthusiastic about waiting in line for healthcare?
Show more
Kudos to @Council4IP's @StewartCoke on such a great piece. Claims about "patent thickets" and "evergreening" are misleading. A new patent doesn't extend an old one. When the original expires, generics can copy that version. Newer patents protect improvements that help patients.
Show more
Generics and biosimilars already fill nearly 90% of U.S. prescriptions. If lawmakers want to lower drug costs, they should start with PBMs and other middlemen whose incentives often steer patients away from cheaper alternatives.
Show more
Despite the savings greater biosimilar competition can deliver, Big Pharma continues to game the system to block more affordable alternatives from reaching patients.
Lawmakers should build on recent bipartisan work to advance bipartisan, market-based solutions. More from @Axios:
Show more
"Double patenting" is a myth. You can't patent the same invention twice. Follow-on patents cover genuinely new innovations — like improved formulations, delivery methods, or dosing — and @USPTO has already debunked the idea that the number of patents has any impact on generic entry.
Show more
El proyecto de Ley ETHIC reduciría el costo de los medicamentos recetados y frenaría el abuso del sistema de patentes por parte de las compañías farmacéuticas al abordar la práctica de patentamiento doble. Sin embargo, los cabilderos de la gran industria farmacéutica están trabajando arduamente para detenerlo.
¡Hay que pelear en contra de la codicia de la gran industria farmacéutica! Envía una carta a tu representante y pídele que ponga a los pacientes primero apoyando el proyecto de Ley ETHIC hoy mismo:
----
The ETHIC Act would lower prescription costs and reduce drug company patent abuse by addressing double patenting but Big Pharma's lobbyists are hard at work against it.
Fight back against Big Pharma greed! Send a letter to your representative urging them to put patients first by supporting the ETHIC Act today:
Show more
The U.S. tech transfer system and the $3.3 trillion in economic output it has generated wouldn’t exist without the Bayh-Dole Act. Read @SallyPipes' piece in @Forbes:
Taxpayer-funded research can produce a breakthrough. But turning that breakthrough into an actual medicine, device, or product can still take years and billions of dollars. Bayh-Dole gave private companies a reason to take that risk.
Read more of my latest for @Forbes:
Show more
@RxPricing @axios If we want more affordable alternatives, we should start by addressing PBMs and middlemen that leave patients paying more at the pharmacy counter. We also need to look at how IRA & MFN price controls could be harming incentives for biosimilar investments.
Show more
DYK: Canadian patients waited a median of 28.6 weeks — nearly seven months — from a GP referral to specialist treatment in a 2025 physician survey.
Universal coverage doesn't always mean timely care.
Show more
Here's a troubling statistic: 84% of teachers say their supervisors would be concerned if they gave too many low grades.
Equal opportunity means giving every child the chance to rise. Trying to falsely engineer "equal" outcomes is something very different.
Show more
Medicare for All promises coverage for everyone. But coverage doesn't guarantee timely care. CBO has warned that a single-payer system would mean more delays and forgone treatment when demand outpaces the supply of doctors and services.
Show more
Every other market provides actual, upfront prices for consumers before they make a purchase — but not in healthcare.
As @sallypipes writes for @NEWSMAX, “Markets work when consumers can compare prices and choose among competitors. Healthcare should be no exception.”
Show more
Medicare for All promises to make healthcare "free." It can't make doctors, hospital beds, or appointments unlimited.
Read more:
DEI has infiltrated American classrooms under the banner of fairness. But as my colleague Lance Izumi argues, these policies can lower expectations, diminish merit, and leave students less prepared to succeed.
He explores these consequences in his latest book, "The Great Equity Epidemic."
Learn more:
Show more
Medicare for All? Careful what you wish for.
The promise of "free healthcare" sounds appealing. But my latest @Newsmax column examines the trade-offs Americans should know about — from long waits and higher taxes to less choice over coverage.
Show more
Medicare for All is often sold as "free healthcare." But single-payer healthcare has massive trade-offs — including longer waits, reduced access to care, higher taxes, and less patient choice.
Listen to more of my interview on the @TudorDixon Podcast:
Show more
"Finding breast cancer early can mean the difference between life and death. Eight and a half million women don’t need government rules or insurance paperwork making timely imaging harder to obtain."
- BRI Founder & Chair @sallypipes on #breastcancer#
Show more
DEI was supposed to make education "fairer." But a new book by @PacificResearch's Lance Izumi argues that too often, policies adopted in its name have lowered academic standards, weakened discipline, and pushed merit and individual achievement aside.
Read "The Great Equity Epidemic" here:
Show more
Doctors are drawing the short stick under Medi-Cal. When the government reimburses physicians well below what private insurers pay, it shouldn't surprise anyone when fewer doctors can afford to participate.
And patients ultimately pay the price.
Show more
High-deductible plans aren't right for everyone. Neither are low-deductible plans. That's precisely why Washington shouldn't wipe one option off the table.
Let patients choose the trade-off between premiums, deductibles, and savings that works best for them.
Show more
I grew up in Canada, where I've seen the country's single-payer healthcare system firsthand. Today, Canadians still struggle with extremely long waits for care.
I joined the @TudorDixon Podcast to discuss what Canada's experience can teach us about Medicare for All:
Show more
